retatrutide trial Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and Retatrutide: What It Is &

This broader mechanism may explain why retatrutide has shown especially strong weight loss results in early trials, though semaglutide currently has the advantage of regulatory approval and longer-term real-world data

It is a triple agonist, meaning that it mimics three different hormones GLP-1, GIP, and glucagon to reduce appetite, manage blood sugar, and increase metabolism and fat breakdown in the body

E., Leoncini, R., Casnici, C., et al

The three-way comparison of semaglutide, tirzepatide, and retatrutide provides the most detailed head-to-head analysis available

Meet some of the consumers touched by our programs

One of the most significant concerns is the efficacy gap between oral and injectable GLP-1 treatments